Hepatitis C virus (HCV) is a highly prevalent virus and one of the major agents of chronic hepatitis. Since HCV NS3 protease is essential for the processing of HCV polyprotein, this protease is a target of choice to control HCV replication. Peptide inhibitors of NS3 were developed by selective amino acid replacement of six leader sequences, corresponding to regions of HCV polyprotein that are cleaved by NS3. The large numbers of potential 14-mer and 16-mer peptide inhibitors thus obtained were tested against NS3 using the fluorescent probe RETS1 and peptide cofactor SVVIVGRIILSGRA from NS4A protein. This afforded several peptide inhibitors with an IC50 of around 2 μM. These peptides may be good leading compounds for the development of peptidomimetics to control HCV replication in the treatment of chronic hepatitis C.
AthertonELoganJC & SheppardRC (1989) Peptide synthesis II. Procedures for solid phase synthesis using N-fluorenyl methoxycarbonyl aminoacids on polyamide supports. Sintesis of substance P and of acyl carrier protein 65–74 decapeptide. Journal of the Chemical Society (Prekin Transactions)1: 538–546.
2.
AttwoodMRBennettJMCampbellADCanningGGCarrMGConwayEDunsdonRMGreeningJRJonesPSKayPBHandaBKHurstDNJenningsNSJordanSKeechEO'BrienMAOvertonHAKing-UnderwoodJRaynhamTMStensonKPWilkinsonCSWilkinsonTC & WilsonFX (1999) The design and synthesis of potent inhibitors of hepatitis C virus NS3–4A proteinase. Antiviral Chemistry & Chemotherapy10: 259–273.
3.
BartenschlagerRAhlborn-LaakeLMousJ & JacobsenH (1994) Kinetic and structural analyses of hepatitis C virus polyprotein processing. Journal of Virology685045–5055.
4.
BennettJMCampbellADCampbellAJCarrMGDunsdonRMGreeningJRHurstDNJenningsNSJonesPSJordanSKayPBO'BrienMAKing-UnderwoodJRaynhamTMWilkinsonCSWilkinsonTC & WilsonFX (2001) The identification of alpha-ketoamides as potent inhibitors of hepatitis C virus NS3–4A proteinase. Bioorganic & Medicinal Chemistry Letters11: 355–357.
5.
BradfordMM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry72: 248–254.
6.
Bruna-RomeroOLasarteJJWilkinsonGGraceKClarkeBBorras-CuestaF & PrietoJ (1997) Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus. Hepatology25: 470–477.
7.
CampsJGarcia-GraneroMRiezu-BojJILarreaEde AlavaECiveiraMPCastillaA & PrietoJ (1994) Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. Journal of Hepatology21: 4–11.
8.
Carrere-KremerSMontpellier-PalaCCocquerelLWychowskiCPeninF & DubuissonJ (2002) Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. Journal of Virology76: 3720–3730.
9.
DimasiNMartinFVolpariCBrunettiMBiasiolGAltamuraSCorteseRDe FrancescoRSteinkuhlerC & SollazzoM (1997) Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires. Journal of Virology71: 7461–7469.
10.
EckartMRSelbyMMasiarzFLeeCBergerKCrawfordKKuoCKuoGHoughtonM & ChooQL (1993) The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochemical & Biophysical Research Communications192: 399–406.
11.
FaillaCTomeiL & De FrancescoR (1994) Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus non-structural proteins. Journal of Virology68: 3753–2760.
12.
FoyELiKWangCSumpterRJrIkedaMLemonSM & GaleMJr (2003) Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science300: 1145–1148.
13.
GlunzPWDoutyBD & DeciccoCP (2003) Design and synthesis of bicyclic pyrimidinone-based HCV NS3 protease inhibitors. Bioorganic & Medicinal Chemistry Letters13: 785–788.
14.
Gonzalez-NavarroC (1997) Expresión y caracterización de la región NS3 del virus C de la hepatitis (HCV). Desa rollo de inhibidores peptidios de la proteina Cpro2. (PhD thesis). In: Genética. Navarra: Universidad de Navarra (in Spanish).
15.
GrakouiAMcCourtDWWychowskiCFeinstoneS. M. and RiceCM (1993a) Characterization of the hepatitis C virus-encoded serine proteinase: Determination of proteinase-dependent polyprotein cleavage sites. Journal of Virology67: 2832–2843.
16.
GrakouiAMcCourtDWWychowskiCFeinstoneSM & RiceC. M. (1993b) A second hepatitis C virus-encoded proteinase. Proceedings of the National Academy of Science, USA90: 10583–10587.
17.
GrakouiAWychowskiCLinC.FeinstoneSM & RiceCM (1993c) Expression and identification of hepatitis C virus polyprotein cleavage products. Journal of Virology67: 1385–1395.
18.
GriffinSDBealesLPClarkeDSWorsfoldOEvansSDJaegerJHarrisMP & RowlandsDJ (2003) The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Letters535: 34–38.
19.
HahmBHanDSBackSHSongOKChoMJKimCJShimotohnoK & JangSK (1995) NS3–4A of hepatitis C virus is a chymotrypsin-like protease. Journal of Virology69: 2534–2539.
HijikataMMizushimaHAkagiTMoriSKakiuchiNKatoNTanakaTKimuraK & ShimotohnoK (1993a) Two distinct proteinase activities required for the processing of a putative non-structural precursor protein of hepatitis C virus. Journal of Virology67: 4665–4675.
22.
HijikataMMizushimaHTanjiYKomodaYHirowatariYAkagiTKatoNKimuraK & ShimotohnoK (1993b) Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proceedings of the National Academy of Science, USA90: 10773–10777.
23.
HoughtonMWeinerAHanJKuoG & ChooQL (1991) Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease. Hepatology14: 381–388.
24.
IngallinellaPAltamuraSBianchiETalianiMIngenitoRCorteseRDe FrancescoRSteinkuhlerC & PessiA (1998) Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry37: 8906–8914.
25.
IngallinellaPBianchiEIngenitoRKochUSteinkuhlerCAltamuraS & PessiA (2000) Optimization of the P'-region of peptide inhibitors of hepatitis C virus NS3/4A protease. Biochemistry39: 12898–12906.
KimJLMorgensternKALinCFoxTDwyerMDLandroJAChambersSPMarklandWLepreCAO'MalleyETHarbesonSLRiceCMMurckoMACaronPR & ThomsonJA (1996) Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell87: 343–355.
28.
KrausslichHOroszlamS & WimmerE (1989) Viral Proteinases as Targets for Chemotherapy. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
29.
LaVallieERDiBlasioEAKovacicSGrantKLSchendelPF & McCoyJM (1993) A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Biotechnology (NY)11: 187–193.
30.
LeyssenPDe ClercqE & NeytsJ (2000) Perspectives for the treatment of infections with Flaviviridae. Clinical Microbiology Reviews13: 67–82.
31.
LinCLindenbachBDPragaiBMMcCourtDW & RiceCM. (1994) Processing in the hepatitis C virus E2-NS2 region: Identification of p7 and two distinct E2-specific products with different C termini. Journal of Virology68: 5063–5073.
32.
LoveRAPargeHEWickershamJAHostomskyZHabukaNMoomawEWAdachiT & HostomskaZ (1996) The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell87: 331–342.
33.
Llinas-BrunetMBaileyMFazalGGouletSHalmosTLaplanteSMauriceRPoirierMPoupartMAThibeaultDWernicD & LamarreD (1998) Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorganic & Medicinal Chemistry Letters8: 1713–1718.
34.
MannsMPMcHutchisonJGGordonSCRustgiVKShiffmanMReindollarRGoodmanZDKouryKLingM & AlbrechtJK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet358: 958–965.
35.
McHutchisonJGShadJAGordonSCMorganTRLingMHGaraudJJAlbrechtJK & DienstagJL (2001) Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. Journal of Viral Hepatitis8: 414–420.
36.
MerrifieldRB (1963) Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. Journal of the American Chemical Society85: 2149–2154.
37.
MizushimaHHijikataMTanjiYKimuraK & ShimotohnoK. (1994) Analysis of N-terminal processing of hepatitis C virus non-structural protein 2. Journal of Virology68: 2731–2734.
38.
PavlovicD.NevilleD. C.ArgaudO.BlumbergBDwekR. A.FischerW. B. and ZitzmannN (2003) The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proceedings of the National Academy of Science, USA100: 6104–6108.
39.
SakamuroDFurukawaT & TakegamiT (1995) Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. Journal of Virology69: 3893–3896.
40.
ShimotohnoKTanjiYHirowatariYKomodaYKatoN & HijikataM (1995) Processing of the hepatitis C virus precursor protein. Journal of Hepatology22: 87–92.
41.
ShojiISuzukiTChiedaS.SatoMHaradaTChibaTMatsuuraY & MiyamuraT (1995) Proteolytic activity of NS3 serine proteinase of hepatitis C virus efficiently expressed in Escherichia coli. Hepatology22: 1648–1655.
42.
SinghJ (1992) Atlas of Protein Side-Chain Interactions. Oxford: IRL Press.
43.
SteinkuhlerCTomeiL & De FrancescoR (1996a) In vitro activity of hepatitis C virus protease NS3 purified from recombinant Baculovirus-infected Sf9 cells. Journal of Biological Chemistry271: 6367–6373.
44.
SteinkuhlerCUrbaniATomeiLBiasiolGSardanaMBianchiEPessiA & De FrancescoR (1996b) Activity of purified hepatitis C virus protease NS3 on peptide substrates. Journal of Virology70: 6694–6700.
45.
SudoKMatsumotoYMatsushimaMFujiwaraMKonnoKShimotohnoKShigetaS & YokotaT (1997) Novel hepatitis C virus protease inhibitors: Thiazolidine derivatives. Biochemical & Biophysical Research Communications238: 643–247.
46.
TakamizawaAMoriCFukeIManabeSMurakamiSFujitaJOnishiEAndohTYoshidaI & OkayamaH (1991) Structure and organization of the hepatitis C virus genome isolated from human carriers. Journal of Virology65: 1105–1113.
47.
TalianiMBianchiENarjesFFossatelliMUrbaniASteinkuhlerCDe FrancescoR and PessiA (1996) A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates. Analytical Biochemistry240: 60–67.
48.
TanakaTKatoNNakagawaMOotsuyamaYChoMJNakazawaTHijikataMIshimuraY and ShimotohnoK (1992) Molecular cloning of hepatitis C virus genome from a single Japanese carrier: Sequence variation within the same individual and among infected individuals. Virus Research23: 39–53.
49.
TanjiYHijikataMHirowatariY & ShimotohnoK (1994) Identification of the domain required for trans-cleavage activity of hepatitis C viral serine proteinase. Gene145: 215–219.
50.
TanjiYHijikataMSatohSKanekoT & ShimotohnoK (1995) Hepatitis C virus-encoded nonstructural protein NS4A has versatile functions in viral protein processing. Journal of Virology69: 1575–1581.
51.
TomeiLFaillaCVitaleRLBianchiE & De FrancescoR. (1996) A central hydrophobic domain of the hepatitis C virus NS4A protein is necessary and sufficient for the activation of the NS3 protease. Journal of General Virology77: 1065–1070.
52.
WHO (1997) Hepatitis C. Weekly Epidemiological Record72: 65.
53.
ZhangXSchmittACJiangWWassermanZ & DeciccoCP (2003) Design and synthesis of potent, non-peptide inhibitors of HCV NS3 protease. Bioorganic & Medicinal Chemistry Letters13: 1157–1160.
54.
ZoulimFChevallierMMaynardM & TrepoC (2003) Clinical consequences of hepatitis C virus infection. Reviews in Medical Virology13: 57–68.
